Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761228
https://www.globenewswire.com/news-release/2024/06/18/2900276/0/en/Immunocore-announces-randomization-of-first-patient-in-the-global-registrational-Phase-3-clinical-trial-testing-brenetafusp-for-the-treatment-of-first-line-advanced-or-metastatic-c.html
https://www.globenewswire.com/news-release/2024/06/01/2891808/0/en/Immunocore-presents-KIMMTRAK-clinical-data-demonstrating-that-patients-with-stable-disease-and-confirmed-tumor-reduction-have-similar-clinical-outcomes-to-patients-with-partial-res.html
https://www.globenewswire.com/news-release/2024/05/31/2891735/0/en/Immunocore-reports-updated-Phase-1-data-of-brenetafusp-IMC-F106C-an-ImmTAC-bispecific-targeting-PRAME-in-immune-checkpoint-pre-treated-cutaneous-melanoma-patients-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/05/30/2891106/0/en/Immunocore-to-present-at-the-Jefferies-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/29/2889681/0/en/Immunocore-converts-Phase-2-3-TEBE-AM-clinical-trial-into-registrational-Phase-3-trial-evaluating-KIMMTRAK-for-previously-treated-advanced-cutaneous-melanoma.html
https://www.globenewswire.com/news-release/2024/05/08/2877629/0/en/Immunocore-reports-first-quarter-financial-results-and-provides-a-business-update.html
https://www.globenewswire.com/news-release/2024/04/24/2868741/0/en/Immunocore-announces-upcoming-presentation-and-posters-at-ASCO-2024.html
https://www.globenewswire.com/news-release/2024/04/04/2858173/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html
https://www.globenewswire.com//news-release/2024/03/05/2840934/0/en/Immunocore-presented-two-posters-at-CROI-2024.html